Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2011-04-26
2011-04-26
Andres, Janet L (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S428000, C548S568000
Reexamination Certificate
active
07932421
ABSTRACT:
The present invention provides N-cyclohexyl benzamide and benzeneacetamide compounds according to formula (I):where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, m, n, p, and q are as defined in the description; as well as pharmaceutical compositions comprising the same, methods of use of the compounds and compositions of the invention for the treatment of conditions associated with hydroxysteroid dehydrogenases (e.g., 11β-HSD1), and the use of the compounds of the invention in the preparation of medicaments for the treatment of hydroxysteroid dehydrogenase-associated conditions.
REFERENCES:
patent: 3536809 (1970-10-01), Allplezwqeip
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee et al.
patent: 5059595 (1991-10-01), Le Grazie et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5112598 (1992-05-01), Biesalski
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5556611 (1996-09-01), Biesalski
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van Der Linden et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: 2007/0167497 (2007-07-01), Nambu et al.
patent: 0 431 580 (1991-06-01), None
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 97/39745 (1997-10-01), None
patent: WO 99/47196 (1999-09-01), None
patent: WO 2004/089896 (2004-10-01), None
patent: WO 2005/095357 (2005-10-01), None
patent: WO 2005/116029 (2005-12-01), None
patent: WO 2007/145835 (2007-12-01), None
Hcaplus 1967:507891 abstract, “Leuckart reaction with 4-tert-butylcyclohexanone”, Hey et. al., 1967.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Hcaplus 1976:507891 abstract, “Leuckart reaction with 4-tert-butylcyclohexanone”, Hey et. al., 1967.
Hcaplus 1986:406405 abstract, “Aminohydroxyalkylcycloalkylbenzeneacetamides and -benzamides”, Kaplan, Lester Jay, 1986.
Patani et. al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 1996, 96, pp. 3147-3176.
Hcaplus 1969:19398, “Clearage of oxazolidine rings with metal catalysts. II. Stereochemisty”, Bernardi et. al., 1968.
Hcaplus 2004:633903, “Preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1”, Coppola et. al., 2004.
Hcaplus 2005:1012143, “Perhydroquinolylbenzamides as Novel Inhibitors of 11 Beta-hydroxysteroid Dehydrogenase Type 1”, 2005, Coppola et. al.
Hcaplus 1986:406405, “Aminohydroxyalkylcycloalkylbenzeneacetamides and benzamides”, Kaplan, Lester Jay, 1986.
Barf et al., J. Med. Chem. 2002, 45: pp. 3813-3815.
Bellows et al., Bone 1998, 23: pp. 119-125.
Billaudel et al., Horm. Metab. Res. 1979, 11: pp. 555-560.
Buchwald et al., Surgery, 1980, 88, p. 507.
Bujalska et al., Lancet 1997, 349: pp. 1210-1213.
Burger's Medicinal Chemistry and Drug Discovery, 6thed. (Donald J. Abraham ed., 2001, Wiley).
Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984).
Cooper et al., Bone 2000, 27: pp. 375-381.
Dahl et al., Poster 524 at American Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
Davani et al., J. Biol. Chem. 2000, 275: pp. 34841-34844.
de Quervain et al., Nature 1998, 394: pp. 787-790.
Design and Application of Prodrugs(H. Bundgaard ed., 1985, Harwood Academic Publishers Gmfh).
During et al., Ann. Neurol., 1989, 25, p. 351.
Engelke et al., Poster 342 at American Association of Cancer Research, San Francisco, Calif., Apr. 1-5, 2000.
English et al., J. Clin. Endocrinol. Metab. 1999, 84: pp. 2080-2085.
Fraser et al., Hypertension 1999, 33: pp. 1364-1368.
Ge et al., Biology of Reproduction 1999, 60: pp. 855-860.
Geissler et al., Nat. Genet. 1994, 7: pp. 34-39.
Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115 (1984).
Halleux et al., J. Clin. Endocrinol. Metab. 1999, 84: pp. 4097-4105.
Houssay, Endocrinology 1942, 30: pp. 884-892.
Howard et al., J. Neurosurg., 1989, 71, p. 105.
Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia, PA (1985).
Jamieson et al., J. Endocrinol. 2000, 165: pp. 685-692.
Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-380.
Kim et al., J. Endocrinol. 1999, 162: pp. 371-379.
Kitawaki et al., J. Clin. Endocrin. Metab. 2000, 85: pp. 3292-3296.
Kotelevtsev et al., Proc. Natl. Acad. Sci. USA 1997, 94: pp. 14924-14929.
Labrie et al., Mol. Cell. Endocrinol. 1991, 78: pp. C113-C118.
Langer, Science, 1990, 249, 1527.
Levy et al., Science, 1985, 228, p. 190.
Long et al., J. Exp. Med. 1936, 63: pp. 465-490.
Mason, Immunology Today 1991, 12: pp. 57-60.
Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press, Boca Raton, Fla. (1974).
Nobel et al., Eur. J. Biochem. 2001, 268: pp. 4113-4125.
Peltoketo et al., J. Mol. Endocrinol. 1999, 23: pp. 1-11.
Penning et al., Biochem. J. 2000, 351: pp. 67-77.
Quattropani et al., J. Clin. Invest. Nov. 2001, 108: pp. 1299-1305.
Rajan et al., Neuroscience 1996, 16: pp. 65-70.
Raleigh et al., Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, p. 397.
Langer and Peppas, J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23, p. 61.
Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton, PA (1990).
Rook, Baillier's Clin. Endocrinol. Metab. 2000, 13: pp. 576-581.
Saudek et al., New Engl. J. Med., 1989, 321, p. 574.
Seckl et al., Endocrinology 2001, 142: pp. 1371-1376.
Seckl et al., Neuroendocrinol. 2000, 18: pp. 49-99.
Sefton, CRC Crit. Ref. Biomed. Eng., 1987, 14, p. 201.
Stokes et al., Invest. Ophthalmol. 2000, 41: pp. 1629-1638.
Tronche et al., Nature Genetics 1999, 23: pp. 99-103.
Walker et al., Hypertension 1998, 31: pp. 891-895.
Walker et al., poster P3-698 at the Endocrine Society meeting Apr. 12-15, 1999, San Diego.
Woods et al., Science 1998, 280:1378-1383.
Yau et al., Proc Natl. Acad. Sci. USA 2001, 98: pp. 4716-4721.
Drake, Ross, “Polycyclic compounds containing nitrogen. I. The Diels-Alder reaction of 1-nitro-1-alkenens.”,J. Org. Chem., vol. 23, 1958, pp. 717-720. XP002480858.
Ferber, Leonhardt, “Zur Zenntnis der [p-Amino-cyclohexyl]-essigsaure”,Chemische Berichte, vol. 67, 1934, pp. 245-249, XP002480857.
Johnson, et al., “The influence of a methyl substituent on the microbiological oxygenation of cyclic compounds.”,J. Am. Chem. Soc., vol. 93, 1971, pp. 4880-4883. XP002480860.
Johnston, et al., “Synthesis of analogues of N-(2-chloroethyl)-N′-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anti cancer agents”,J.Med. Chem., vol. 20, No. 2, 1977, pp. 279-290. XP002480859.
Partial International Search Report for International Application No. PCT/US2007/025360 dated Oct. 16, 2008. (3 pgs.).
Han Nianhe
Liu Qingyian
McMinn Dustin
Powers Jay
Yuan Chester Chenguang
Amgen Inc.
Andres Janet L
Lemoine Elsa D.
Reese Heidi
LandOfFree
N-cyclohexyl benzamides and benzeneacetamides as inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-cyclohexyl benzamides and benzeneacetamides as inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-cyclohexyl benzamides and benzeneacetamides as inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724042